Tramadol hydrochloride
Poltram Retard is a pain reliever that acts on the central nervous system (brain and spinal cord).
The indication for use of the medicine is moderate to severe pain.
The medicine is intended for use in adults and adolescents over 14 years of age.
Before starting treatment with Poltram Retard, the patient should discuss it with their doctor or pharmacist:
fainting) or if the patient has consciousness disorders of unknown origin;
Care should be taken in patients with respiratory depression, as well as when using other medicines that act depressively on the central nervous system or in significant excess of the recommended doses, as respiratory depression cannot be ruled out in these cases (see section 2 "Poltram Retard and other medicines").
Sleep apnea
Poltram Retard may cause sleep apnea, such as sleep apnea (pauses in breathing during sleep) and hypoxemia (low oxygen level in the blood). Symptoms may include pauses in breathing during sleep, nighttime awakenings due to shortness of breath, difficulty maintaining sleep, or excessive daytime sleepiness. If the patient or another person notices these symptoms, they should contact a doctor. The doctor may consider reducing the dose.
If the patient experiences any of the following symptoms while using Poltram Retard, they should tell their doctor or pharmacist:
Tolerance, dependence, and addiction
This medicine contains tramadol, which is an opioid medicine. Repeated use of opioids can lead to decreased effectiveness of the medicine (the patient's body gets used to the medicine, which is called tolerance). Repeated use of Poltram Retard can also lead to dependence, abuse, and addiction, which can cause life-threatening overdose. The risk of these side effects may increase with dose and duration of treatment.
Dependence or addiction can cause the patient to lose control over the amount of medicine taken or the frequency of its use.
The risk of dependence on Poltram Retard is different for different people. A higher risk of dependence on Poltram Retard may apply to people in the following situations:
If the patient notices any of the following symptoms while taking Poltram Retard, it may indicate dependence or addiction.
Tramadol should not be used for substitution therapy in patients addicted to opioids, as it does not eliminate the symptoms that occur after morphine withdrawal.
Tramadol is converted in the liver by an enzyme. In some patients, there is a certain variant of this enzyme, which can have different effects. In some patients, pain relief may not be sufficient, and in others, the risk of serious side effects may be higher. The patient should stop using the medicine and immediately consult a doctor if they experience any of the following side effects (due to tramadol toxicity): slowed breathing or shallow breathing, confusion, drowsiness, pinpoint pupils, nausea, or vomiting, constipation, loss of appetite.
Do not use the medicine in children and adolescents under 14 years of age, with a body weight of less than 50 kg.
Use after surgical procedures in children
Cautious use of tramadol in children for pain relief after surgery; the patient should be closely monitored for signs of tramadol toxicity (see above), including respiratory depression.
Use in children with respiratory disorders
Tramadol is not recommended for use in children with respiratory disorders, as the symptoms of tramadol toxicity (see above) may be exacerbated in them.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Poltram Retard should not be used at the same time as MAO inhibitors (medicines whose active substance is: isocarboxazid, iproniazid, tranylcypromine, clorgyline, selegiline, moclobemide) - see section "When not to use Poltram Retard".
It is not recommended to use Poltram Retard at the same time as the following medicines:
The risk of side effects is higher if the following medicines are taken at the same time:
Alcohol should not be consumed during treatment.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor or pharmacist before using this medicine.
Poltram Retard should not be used during pregnancy and breastfeeding.
Breastfeeding
Tramadol is excreted into breast milk. Therefore, during breastfeeding, Poltram Retard should not be taken more than once, or if Poltram Retard has been taken more than once, breastfeeding should be stopped.
The medicine may prolong the reaction time, even when used in recommended doses, especially when used at the same time as other psychotropic medicines.
The patient should not drive vehicles or operate machines while using the medicine.
This medicine should always be used exactly as prescribed by the doctor or pharmacist. In case of doubts, the patient should consult a doctor or pharmacist.
Before starting treatment and regularly during treatment, the doctor will discuss with the patient what to expect from using Poltram Retard, when and for how long to take it, when to contact the doctor, and when to stop the medicine (see also section 2).
The dose should be adjusted according to the severity of the pain and the individual response of the patient to the treatment. The patient should take the smallest dose that effectively relieves the pain.
Do not use the medicine in children and adolescents under 14 years of age, with a body weight of less than 50 kg.
The usual initial dose is 50 mg or 100 mg of tramadol twice a day, in the morning and evening. If a lower initial dose than 100 mg is necessary, another tramadol hydrochloride product should be used. If the pain-relieving effect is insufficient, the dose can be gradually increased to 150 mg or 200 mg of tramadol twice a day. The principle of selecting the lowest effective pain-relieving dose should be followed. Usually, a dose higher than 400 mg per day, in divided doses, is not necessary. The tablets should be swallowed whole, without chewing or crushing. The medicine should be taken with a small amount of liquid; it can be taken regardless of meals, preferably in the morning and evening.
In patients over 75 years of age, the elimination of tramadol from the body may be delayed. In these patients, the doctor may recommend prolonging the time interval between doses.
Poltram Retard should not be taken in case of severe hepatic or renal impairment.
In case of mild or moderate impairment, the doctor may recommend prolonging the time interval between doses.
The medicine should not be used for longer than absolutely necessary. In long-term pain treatment, the doctor should periodically check the patient's condition to assess whether and at what dose the treatment should be continued (if necessary, breaks in medication should be made) (see section 2 "Warnings and precautions").
In patients with a tendency to abuse drugs and drug dependence, treatment with tramadol should be short-term and under close medical supervision (see section 2 "Warnings and precautions").
In case of accidental, single ingestion of a double dose of the medicine, medical intervention is usually not necessary. The patient should continue taking the medicine in the dose determined by the doctor and at the usual time intervals.
In case of ingestion of a higher dose of the medicine, the patient should contact a doctor as soon as possible.
Symptoms of overdose are: disorders of consciousness up to coma (a state of deep unconsciousness), seizures, drop in blood pressure, rapid heartbeat (tachycardia), pinpoint pupils, slowed breathing up to respiratory arrest, and inhibition of intestinal peristalsis.
If a dose is missed, the medicine should be taken as soon as possible. If it is already time for the next dose, the missed dose should not be taken. A double dose should not be taken to make up for the missed dose.
The medicine should not be stopped abruptly without the doctor's advice. If the patient wants to stop using the medicine, they should discuss it with their doctor, especially if the medicine has been used for a long time.
The doctor will advise when and how to stop the medicine; this may involve gradually reducing the dose to minimize the risk of side effects (withdrawal symptoms).
If the patient has any further doubts about using this medicine, they should consult a doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
anaphylactic shock (a life-threatening sudden drop in blood pressure due to an allergic reaction, characterized by dizziness, disorientation, and fainting) - occurs rarely.
allergic reactions (occur rarely; shortness of breath, feeling of pressure in the chest due to bronchospasm, wheezing, angioedema, whose symptoms are swelling of the skin and mucous membranes, e.g., throat or tongue, and difficulty breathing and (or) itching, rash, hives - occur not very often).
cardiovascular collapse, whose symptom is, among other things, fainting (occurs not very often);
slower than normal heart rate (occurs rarely).
slowed breathing, shortness of breath up to complete respiratory arrest (occur rarely), exacerbation of asthma, although a causal relationship has not been established.
urinary disorders, urinary retention (occurs rarely).
dependence.
withdrawal symptoms: agitation, restlessness, anxiety, nervousness, insomnia, hyperactivity, tremors, and gastrointestinal disorders. See also section 3.
The following side effects may occur during treatment with the medicine:
Nausea, dizziness.
Headache, drowsiness, fatigue, vomiting, constipation, dry mouth, excessive sweating.
Disorders of heart and circulatory system function (palpitations, rapid heartbeat, decreased blood pressure when changing position), belching, feeling of fullness in the abdominal cavity, diarrhea.
Increased blood pressure, disorders of appetite, feeling of burning or tingling in the limbs without apparent cause (paresthesia), tremors, muscle weakness, involuntary muscle contractions, coordination disorders, slowed breathing, shortness of breath, seizures, hallucinations, anxiety, disorientation, sleep disorders, and nightmares.
After using Poltram Retard, psychiatric disorders may occur. Their severity and type may vary (depending on the patient's personality and duration of treatment). These may include, for example, mood disorders (usually excitement, sometimes irritability), changes in activity (usually decreased, sometimes increased), excessive fatigue, and decreased sensory and cognitive perception (changes in sensations and recognition, which can lead to incorrect assessment of the situation).
Flushing of the face, hot flashes, speech disorders, dilated pupils, swelling, hiccups, serotonin syndrome, whose symptoms may include changes in mental state (e.g., agitation, hallucinations, coma), as well as other symptoms, such as fever, rapid heartbeat, unstable blood pressure, involuntary muscle contractions, muscle stiffness, lack of coordination, and (or) gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) (see section 2, Important information before using Poltram Retard).
The side effects that may occur after sudden withdrawal of the medicine are the same as those after withdrawal of other opioids: agitation, restlessness, anxiety, nervousness, insomnia, hyperactivity, tremors, and gastrointestinal disorders.
Other side effects that have rarely occurred after withdrawal of tramadol include: panic attacks, severe anxiety, hallucinations, paresthesia, ringing in the ears, and other symptoms from the central nervous system (e.g., disorientation, delusions, depersonalization, derealization, paranoia).
If side effects occur, including any side effects not listed in this leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.
Store in the original packaging to protect from moisture.
The medicine should be kept out of sight and reach of children.
This medicine should be stored in a closed and secure place, to which other people do not have access. It can cause serious harm and be fatal to people for whom it has not been prescribed.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
The inscription on the packaging after the abbreviation EXP means the expiry date, and after the abbreviation Lot/LOT means the batch number.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Poltram Retard 100: white, round, biconvex prolonged-release tablets.
Poltram Retard 150: white, oval prolonged-release tablets.
Poltram Retard 200: white, oval prolonged-release tablets.
Packaging contains 10, 30, or 50 tablets in blisters.
Not all pack sizes may be marketed.
Zakłady Farmaceutyczne POLPHARMA S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański
phone: +48 22 364 61 01
Zakłady Farmaceutyczne POLPHARMA S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański
Medochemie Ltd., Facility A - Z, Mich. Erakleous
Ayios Athanassios Industrial Area
Limassol, Cyprus
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.